PubMed Health⌕ Search

Biomedical subjects

K B Delclos

Publications and source records attributed to K B Delclos.

46 records · Page 3Linked to original sources

Identification of ascorbic acid as the heat-stable factor from brain which inactivates the phorbol ester receptor.

Homogenates of calf cortex contained a heat-stable, low-molecular-weight factor which inhibited in a dose-dependent, irreversible, and noncompetitive manner the binding of [20-3H]phorbol-12,13-dibutyrate to its receptor in brain particulate preparations. The inhibitory factor was identified as ascorbic acid. As in other cases in which ascorbic acid alters the activity of membrane proteins, inactivation of phorbol ester binding by ascorbic acid was not stereospecific, correlated with stimulation of lipid peroxidation, and could be blocked by inhibitors of lipid peroxidation. Free radical-mediated receptor inactivation could potentially play a role in systems in which phorbol esters stimulate the generation of active oxygen species or fatty acid hydroperoxides. In addition, protection of the [20-3H]phorbol-12,13-dibutyrate receptor from free radical damage would be desirable in the screening of extracts for competitive inhibitory activities.

Animals↗

Specific binding of phorbol ester tumor promoters to mouse tissues and cultured cells.

Phorbol esters bind to mouse tissues and chick embryo fibroblasts in a specific, saturable, and reversible fashion. The binding site, located in the membrane fraction, is heat and protease sensitive. Binding can be measured most readily with [3H]PDBu. Binding of [3H]PDBu is of high affinity and is inhibited competitively by nonradioactive phorbol esters; the dissociation constants of the phorbol esters correspond quantitatively to their respective biological and tumor-promoting activities. Of particular significance, highly inflammatory but weakly promoting or nonpromoting diterpene esters are much less potent than PMA. Binding of [3H]PMA has been measured directly. The results confirm that PMA and PDBu interact at the same major high-affinity binding site. [3H]PDBu binding is entropy driven. The equilibrium dissociation constant is independent of temperature, whereas the off-rate is highly temperature dependent. In vivo, specific binding activity increases during embryonic development. It also shows considerable variation among tissues. In the mouse, highest binding activity, 28 pmole/mg, is in the brain (skin, for example, binds 3.9 pmole/mg). Between regions of he brain, 10-fold differences in binding activity are found. The high level of phorbol ester binding in brain suggests that the phorbol ester receptor plays a functional rather than an exclusively information-transducing role in the cell. Growth of cells in the presence of PDBu causes marked down-modulation of phorbol ester receptors. In the GH4C1 rat pituitary cell line, receptor number is decreased by 80% in 24 hr. In membrane preparations, the phorbol ester binding affinity is calcium sensitive. It has been speculated that endogenous ligands interacting at the phorbol ester receptor may exist. The finding that the supernatant fraction from boiled or acidified brain inhibits [3H]PDBu binding is therefore exciting.

Animals↗

Phorbol ester action is independent of viral and cellular src kinase levels.

Treatment of normal chick embryo fibroblasts with phorbol myristate acetate causes those cells to express many of the phenotypic properties of virally transformed cells and also enhances the expression of transformed properties in Rous sarcoma virus-transformed chick embryo fibroblasts. We report here that phorbol myristate acetate has little or no effect on the level of protein kinases encoded by the viral src or endogenous sarc genes.

Animals↗

Characterization of specific binding of [3H]phorbol 12,13-dibutyrate and [3H]phorbol 12-myristate 13-acetate to mouse brain.

[20-3H]Phorbol 12,13-dibutyrate ([3H]PDBU) and [20-3H]-phorbol 12-myristate 13-acetate ([3H]PMA) bound specifically and with high affinity to one class of saturable binding sites in particulate preparations from mouse brain. The dissociation constants for binding of [3H]PDBU and [3H]PMA were 7 nM and 66 pm, respectively. At half-maximal specific binding, binding of [3H]PDBU was 96% specific and binding of [3H]PMA was 91% specific. At saturation, 28 pmol of [3H]PDBU were bound per mg protein. Nonradioactive phorbol 12-myristate 13-acetate blocked > 95% of the specific [3H]PDBU binding. Conversely, nonradioactive phorbol 12,13-dibutyrate blocked > 95% of the specific [3H]PMA binding. The binding sites in mouse brain for [3H]PDBU and [3H]PMA thus appear to be equivalent. In addition to phorbol 12-myritate 13-acetate, seven other biologically active phorbol-related diterpenes inhibited [3H]PDBU binding with potencies which correlated with their biological activities. In the case of phorbol 12,13-diacetate, inhibition of [3H]PDBU binding was shown to be competitive. Phorbol (20 microgram/ml) and 4 alpha-phorbol 12,13-didecanoate (20 microgram/ml), two compounds devoid of biological activity, had no effect on binding. Binding was sensitive to heat, papain, and phospholipase A2 but was insensitive to neuraminidase. Based on the high level of specific phorbol ester binding in brain, we postulate that the phorbol ester target plays a functional rather than information-transducing role in the cell.

Animals↗

Decrease in collagen production in normal and Rous sarcoma virus-transformed chick embryo fibroblasts induced by phorbol myristate acetate.

The effect of the potent tumor promoter phorbol 12-myristate 13-acetate (PMA) on collagen synthesis, a differentiated property of chick embryo fibroblasts, was examined. Collagen synthesis, as measured by the rate of formation of [3H]hydroxyproline from [3H]proline, was found to be decreased in cells treated with PMA but not in cells treated with the parent alcohol phorbol. The decrease in collagenase-sensitive proteins was confirmed by polyacrylamide gel electrophoresis of cell lysates, indicating that the decrease could not be ascribed simply to an effect on prolyl hydroxylase. Although a decrease in collagen synthesis was observed after one day, five days were required for a maximal reduction to 20% of that of dimethyl sulfoxide-treated controls. The effect of PMA on collagen synthesis was reversible. It was therefore not the result of a permanent transformation of the cells or of the selection of a population of cells with a reduced capacity for collagen synthesis. Collagen synthesis was decreased in chick embryo fibroblasts transformed by Rous sarcoma virus. Treatment of these cells with PMA for 5 days brought about a further decrease to 50% of the level in dimethyl sulfoxide-treated transformed controls.

Animals↗

The role of intestinal microflora in the metabolic activation of 6-nitrochrysene to DNA-binding derivatives in mice.

6-Nitrochrysene has previously been shown to be a potent lung and liver carcinogen following i.p. administration to newborn mice and to be metabolically activated to DNA-binding derivatives by nitro-reduction or a combination of nitro-reduction and ring oxidation. In this study, we have examined fecal metabolites and DNA-carcinogen adducts in 5-week-old conventional and germfree Balb/c mice treated with [3H]6-nitrochrysene in order to determine if the metabolic activation pathway(s) for this compound in these mice differs from that observed in preweanling mice. We further evaluated the role of the intestinal microflora on the metabolism and generation of DNA-reactive metabolites in this system. The amount of 6-aminochrysene excreted in the feces of germfree mice within 48 h after treatment with a single i.p. dose of [3H]6-nitrochrysene (0.03 mumol/5 microliters/g body wt) was approximately 25% of that excreted in identically treated conventional mice. However, the levels of carcinogen-DNA adducts in the lungs and livers of conventional and germfree Balb/c mice were similar at the 24 and 48 h time points examined. HPLC analysis of hydrolysates of liver and lung DNA indicated that adducts derived from both N-hydroxy-6-aminochrysene and trans-1,2-dihydroxy-1,2-dihydro-6-aminochrysene metabolites were formed in the liver whereas only the latter adduct was detected in the lung. This contrasts with previous findings in preweanling mice where the adduct derived from the trans-1,2-dihydroxy-1,2-dihydro-6-aminochrysene metabolite was the single major adduct detected in both liver and lung DNA. The proportion of adducts derived from N-hydroxy-6-aminochrysene was significantly greater in the liver DNA of germfree mice than in the liver DNA of conventional mice.

Animals↗

Placental transfer of the soy isoflavone genistein following dietary and gavage administration to Sprague Dawley rats.

Genistein, the principal soy isoflavone, has estrogenic activity and is widely consumed by humans for putative beneficial health effects. The goal of the present study was to measure placental transfer of genistein in rats as a possible route of developmental exposure. Pregnant Sprague-Dawley rats were administered genistein orally, either by diet or by gavage. Concentrations of genistein aglycone and conjugates were measured in maternal and offspring serum and brain using HPLC with isotope dilution electrospray tandem mass spectrometry. Although fetal or neonatal serum concentrations of total genistein were approximately 20-fold lower than maternal serum concentrations, the biologically active genistein aglycone concentration was only 5-fold lower. Fetal brain contained predominately genistein aglycone at levels similar to those in the maternal brain. These studies show that genistein aglycone crosses the rat placenta and can reach fetal brain from maternal serum genistein levels that are relevant to those observed in humans.

Administration, Oral↗

Effects of dietary genistein exposure during development on male and female CD (Sprague-Dawley) rats.

Genistein is a naturally occurring isoflavone that interacts with estrogen receptors and multiple other molecular targets. Human exposure to genistein is predominantly through consumption of soy products, including soy-based infant formula and dietary supplements. A dose range-finding study was conducted as a prelude to a multigeneration bioassay to assess potential toxicities associated with genistein consumption. Genistein was administered in a soy- and alfalfa-free diet at 0, 5, 25, 100, 250, 625, or 1250 ppm to pregnant dams starting on Gestation day 7 and continuing throughout pregnancy. Dietary exposure of the dams continued through lactation, and pups were maintained on the same dosed feed as their mother after weaning until sacrifice at Postnatal day 50. Body weight and feed consumption of the treated dams prior to parturition showed a decreasing trend with a significant reduction at the highest dose. Litter birth weight was depressed in the 1250 ppm dose group, and pups of both sexes in that dose group had significantly decreased body weights relative to controls at the time of sacrifice. The most pronounced organ weight effects in the pups were decreased ventral prostate weight in males at the 1250 ppm dose and a trend toward higher pituitary gland to body weight ratios in both sexes. Histopathologic examination of female pups revealed ductal/alveolar hyperplasia of the mammary glands at 250 to 1250 ppm. Ductal/alveolar hyperplasia and hypertrophy also occurred in males, with significant effects seen at 25 ppm and above. Abnormal cellular maturation in the vagina was observed at 625 and 1250 ppm, and abnormal ovarian antral follicles were observed at 1250 ppm. In males, aberrant or delayed spermatogenesis in the seminiferous tubules relative to controls was observed at 1250 ppm. There was a deficit of sperm in the epididymis at 625 and 1250 ppm relative to controls, although testicular spermatid head counts and epididymal spermatozoa counts did not show significant differences from controls at these doses. Both sexes showed an increase in the incidence and/or severity of renal tubal mineralization at doses of 250 ppm and above. Dietary genistein thus produced effects in multiple estrogen-sensitive tissues in males and females that are generally consistent with its estrogenic activity. These effects occurred within exposure ranges achievable in humans.

Animals↗

Maternal and offspring toxicity but few sexually dimorphic behavioral alterations result from nonylphenol exposure.

Nonylphenol ethoxylates are used in the production of surfactants and are found in numerous manufactured substances. para-Nonylphenol (NP) is a suspected endocrine disruptor, exhibiting estrogen-like activity and might cause alterations with developmental exposure. To evaluate such effects, pregnant Sprague-Dawley rats consumed diets containing 0 (n = 11), 25 (n = 10), 500 (n = 10), or 2,000 (n = 9) ppm NP beginning on gestational day (GD) 7. At postnatal day (PND) 21, offspring continued on the same maternal diets until PND 77 and were evaluated for behavioral alterations (open-field activity at PNDs 22-24, 43-45, 64-66, play behavior at PND 35, running wheel activity at PND 63-77, flavored solution intake at PND 69-75). During pregnancy and lactation, dams in the 25-, 500-, and 2,000-ppm groups consumed 9 to 25% less food, which was associated with a 17% less weight gain during GDs 1 to 21 in dams of the 2,000-ppm group, although this effect was not statistically significant. Gestation duration, birth weight, sex ratio of live pups, and number of live or dead pups per litter did not differ between treatment groups. Offspring body weight and food consumption were decreased in the 2, 000-ppm group beginning at PND 28; however, an effect of feed aversion could not be eliminated. Behavioral assessments of offspring indicated no consistent NP-related effects in open-field activity at PNDs 22-24, 43-45, and 65-67 nor in running wheel activity at PNDs 63-75. Play behavior at PND 35 and intake of a 0.3% saccharin-flavored solution at PNDs 69-71 did not differ with respect to treatment groups. However, intake of a 3% sodium-flavored solution at PNDs 73-75 was significantly increased in offspring of the 2,000-ppm group and intake of regular water during this same time was also significantly increased. These results indicate that developmental NP treatment results in maternal and offspring toxicity as evidenced by decreased food intake and weight gain. However, behavioral alterations were evident only in increased intake of a sodium solution.

Animals↗